These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30468097)

  • 1. Review of studies reporting actual prices for medicines.
    Mardetko N; Kos M; Vogler S
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing medicine price transparency through price information mechanisms.
    Hinsch M; Kaddar M; Schmitt S
    Global Health; 2014 May; 10():34. PubMed ID: 24885767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
    Mestre-Ferrandiz J; Zozaya N; Alcalá B; Hidalgo-Vega Á
    Pharmacoeconomics; 2018 Dec; 36(12):1407-1420. PubMed ID: 30198061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.
    Morgan SG; Vogler S; Wagner AK
    Health Policy; 2017 Apr; 121(4):354-362. PubMed ID: 28238340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
    Carapinha JL
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):11-4. PubMed ID: 26707161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
    Moodley R; Suleman F
    BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings.
    Russo G; McPake B
    Health Policy Plan; 2010 Jan; 25(1):70-84. PubMed ID: 19843636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
    Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
    PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
    Vogler S; Vitry A; Babar ZU
    Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey.
    Russo P; Carletto A; Németh G; Habl C
    Health Policy; 2021 Sep; 125(9):1140-1145. PubMed ID: 34253396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices.
    Shaw B; Mestre-Ferrandiz J
    Pharmacoeconomics; 2020 Feb; 38(2):125-134. PubMed ID: 31956967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence on the effectiveness of policies promoting price transparency - A systematic review.
    Joosse IR; Tordrup D; Glanville J; Kotas E; Mantel-Teeuwisse AK; van den Ham HA
    Health Policy; 2023 Aug; 134():104681. PubMed ID: 36372608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
    Danzon PM
    Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.